The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2007 Aug 10

PMID 17687635

Citations 13

Authors

Necati Dagli

Mustafa Yavuzkir

Ilgin Karaca

Affiliations

Soon will be listed here.

Abstract

Objective: Coronary artery disease (CAD) is presently the major cause of mortality and morbidity. Anti-hyperlipidemic treatment is one of the main treatment steps in the management of CAD. Statins are the cornerstones in this treatment. Ezetimibe can be reliably used, when statins prove ineffective in treatment, or to reduce their side effects. In the present study we examined the effects of high-dose pravastatin (40 mg) and low-dose pravastatin (10 mg) + ezetimibe (10 mg) combination therapy on lipid and glucose mechanism, as well as inflammation.

Methods: This study registered 100 cases. Of the cases, 50 [57.1 +/- 11.1 years (24 (48%) females and 26 (52%) males)] were administered 40 mg/day pravastatin (group 1) and 50 [53.2 +/- 12.2 years (27 (54%) females and 23 (46%) males)] were administered 10 mg pravastatin + 10 mg ezetimibe (group 2).

Results: In group 1, total cholesterol fell from 231.1 +/- 83.5 mg/dl to 211.3 +/- 37.2 mg/dl (p = 0.03), triglyceride from 243.5 +/- 96.8 mg/dl to 190.9 +/- 55.2 mg/dl (p = 0.003), and LDL cholesterol from 165.7 +/- 29.7 mg/dl to 133.4 +/- 26.6 mg/dl (p = 0.02). In group 2, total cholesterol dropped from 250.9 +/- 51.8 mg/dl to 187.9 +/- 34.9 mg/dl (p = 0.001), triglyceride from 270.3 +/- 158.9 mg/dl to 154.6 +/- 60.7 mg/dl (p = 0.001), and LDL cholesterol from 158.1 +/- 47.5 mg/dl to 116.9 +/- 26.4 mg/dl (p = 0.001). Insulin resistance decreased from 4.05 +/- 2.31 to 3.16 +/- 1.90 (p = 0.07) in group 1 and from 2.96 +/- 1.50 to 2.05 +/- 0.55 (p = 0.009) in group 2. High sensitive C-reactive protein fell from 6.69 +/- 6.11 mg/l to 3.02 +/- 1.70 mg/l (p = 0.01) in group 1 and from 6.36 +/- 2.06 mg/l to 2.68 +/- 1.69 mg/l (p = 0.001) in group 2.

Conclusion: Both therapy regimes are effective. However, we found that low-dose pravastatin and ezetimibe combination therapy is more effective than high-dose pravastatin therapy on lipid metabolism, glucose metabolism and inflammation.

Citing Articles

Safety and Effectiveness of High-Intensity Statins Versus Low/Moderate-Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis.

Soleimani H, Mousavi A, Shojaei S, Tavakoli K, Salabat D, Rad F Clin Cardiol. 2024; 47(8):e24334.

PMID: 39135464 PMC: 11319735. DOI: 10.1002/clc.24334.

The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials.

Arabi S, Chambari M, Malek-Ahmadi M, Bahrami L, Hadi V, Rizzo M Inflammopharmacology. 2022; 30(5):1597-1615.

PMID: 35988111 DOI: 10.1007/s10787-022-01053-4.

Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.

Gonzalez-Lleo A, Sanchez-Hernandez R, Boronat M, Wagner A Nutrients. 2022; 14(7).

PMID: 35406116 PMC: 9002616. DOI: 10.3390/nu14071503.

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases.

Wan S, Ding Y, Ji X, Meng R Aging Dis. 2021; 12(8):1857-1871.

PMID: 34881073 PMC: 8612613. DOI: 10.14336/AD.2021.0412.

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X Cochrane Database Syst Rev. 2018; 11:CD012502.

PMID: 30480766 PMC: 6516816. DOI: 10.1002/14651858.CD012502.pub2.

References

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

van Heek M, Farley C, Compton D, Hoos L, Davis H . Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001; 134(2):409-17. PMC: 1572957. DOI: 10.1038/sj.bjp.0704260. View

Leitersdorf E . Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int J Clin Pract. 2002; 56(2):116-9. View

Fontbonne A . Why can high insulin levels indicate a risk for coronary heart disease?. Diabetologia. 1994; 37(9):953-5. DOI: 10.1007/BF00400954. View

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269(23):3015-23. View

Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles J . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344(26):1959-65. DOI: 10.1056/NEJM200106283442601. View

Ginsberg H . Treatment for patients with the metabolic syndrome. Am J Cardiol. 2003; 91(7A):29E-39E. DOI: 10.1016/s0002-9149(02)03386-6. View

van Heek M, France C, Compton D, McLeod R, Yumibe N, Alton K . In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997; 283(1):157-63. View

10.

Paolisso G, Gambardella A, Galzerano D, DAmore A, Balbi V, Varricchio M . Metabolic features of patients with and without coronary heart disease but with a superimposable cluster of cardiovascular risk factors. Coron Artery Dis. 1993; 4(12):1085-91. DOI: 10.1097/00019501-199312000-00008. View

11.

Albert M, Danielson E, Rifai N, Ridker P . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286(1):64-70. DOI: 10.1001/jama.286.1.64. View

12.

PEARSON T, Laurora I, Chu H, Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4):459-67. DOI: 10.1001/archinte.160.4.459. View

13.

Davis Jr H, Compton D, Hoos L, Tetzloff G . Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001; 21(12):2032-8. DOI: 10.1161/hq1201.100260. View

14.

Primatesta P, Poulter N . Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000; 321(7272):1322-5. PMC: 27537. DOI: 10.1136/bmj.321.7272.1322. View

15.

Libby P . Atherosclerosis: the new view. Sci Am. 2002; 286(5):46-55. DOI: 10.1038/scientificamerican0502-46. View

16.

Murray C, Lopez A . Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349(9061):1269-76. DOI: 10.1016/S0140-6736(96)07493-4. View

17.

van Heek M, Farley C, Compton D, Hoos L, Alton K, Sybertz E . Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000; 129(8):1748-54. PMC: 1571998. DOI: 10.1038/sj.bjp.0703235. View

18.

Despres J, Lamarche B, Mauriege P, Cantin B, Dagenais G, Moorjani S . Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996; 334(15):952-7. DOI: 10.1056/NEJM199604113341504. View

19.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

20.

Ridker P, Rifai N, Pfeffer M, Sacks F, Moye L, Goldman S . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98(9):839-44. DOI: 10.1161/01.cir.98.9.839. View